Literature DB >> 35479419

Datasets comprising the quality validations of simulated protein-ligand complexes and SYBYL docking scores of bioactive natural compounds as inhibitors of Mycobacterium tuberculosis protein-targets.

Sravan Kumar Miryala1, Soumya Basu1, Aniket Naha1, Reetika Debroy1, Sudha Ramaiah1, Anand Anbarasu1, Saravanan Natarajan2.   

Abstract

Docking scores and simulation parameters to study the potency of natural compounds against protein targets in Mycobacterium tuberculosis (Mtb) were retrieved through molecular docking and in-silico structural investigation. The molecular docking datasets comprised 15 natural compounds, seven conventional anti-tuberculosis (anti-TB) drugs and their seven corresponding Mtb target proteins. Mtb protein targets were actively involved in translation mechanism, nucleic acid metabolism and membrane integrity. Standard structural screening and stereochemical optimizations were adopted to generate the 3D protein structures and their corresponding ligands prior to molecular docking. Force-field integration and energy minimization were further employed to obtain the proteins in their ideal geometry. Surflex-dock algorithm using Hammerhead scoring functions were used to finally produce the docking scores between each protein and the corresponding ligand(s). The best-docked complexes selected for simulation studies were subjected to topology adjustments, charge neutralizations, solvation and equilibrations (temperature, volume and pressure). The protein-ligand complexes and molecular dynamics parameter files have been provided. The trajectories of the simulated parameters such as density, pressure and temperature were generated with integrated tools of the simulation suite. The datasets can be useful to computational and molecular medicine researchers to find therapeutic leads relevant to the chemical behaviours of a specific class of compounds against biological systems. Structural parameters and energy functions provided a set of standard values that can be utilised to design simulation experiments regarding similar macromolecular interactions.
© 2022 The Author(s). Published by Elsevier Inc.

Entities:  

Keywords:  Docking; Natural compounds; Simulation; Therapeutics; Tuberculosis

Year:  2022        PMID: 35479419      PMCID: PMC9035630          DOI: 10.1016/j.dib.2022.108146

Source DB:  PubMed          Journal:  Data Brief        ISSN: 2352-3409


Specifications Table

Value of the Data

There are four distinct types of datasets presented in this manuscript: like Crash score, G-score, PMF score, d-score, Chem scoresand C-scores can help understand different chemical factors affecting ligand-protein binding. will provide comprehensive idea about the fundamental format of input biomolecular structural complexes to run molecular dynamics simulations. will definitely facilitate in further analysis and performing essential dynamics studies besides guiding researchers to replicate similar experimental approaches and objectives. regarding individual protein-ligand complexes can give a fair idea of the set of conditions required to simulate a specific type of biomolecule (protein) interacting with a certain class of compounds. The datasets can be of interest to bioinformaticians, computational biologists, phytochemists and molecular medicine researchers, who can figure out leads relevant to the chemical behaviours of a certain class of compounds against biological systems. The docking scores can further be exploited either based on individual compounds or collective understanding of a specific class of compounds or analysis of specific chemical parameters based on individual scoring algorithms. The compounds that were not considered as per criteria presented in the main publication can further be explored similarly against other potent targets [1]. The optimised simulation parameters can readily guide researchers by providing a set of standard values that can be utilised to design simulation experiments regarding the same/similar macromolecules The simulation profiles may encourage designing of efficient therapeutic agents by providing crucial interaction dynamics values.

Data Description

The presented datasets depict the feasibility of certain classes of natural compounds as therapeutic candidates against Mtb protein targets. Supplementary Files-1–7 (Docking_scores) (https://data.mendeley.com/datasets/94rh86jfpk/3) portrayed the docking scores comprising crash score, G-score, PMF score, d-score, chem scores, polar, total score, consensus (C) score, number of Hydrogen-bonds of the natural compounds against Mtb targets [Arabinosyl transferase (PDB ID: 3PTY); DNA Gyrase subunit A (PDB ID: 4G3N); Ribosomal protein S1 (PDB ID: 4NNI); 2′-O-Methyltransferase (PDB ID: 5KYG); Enoyl (acyl-carrier protein) reductase (PDB ID: 5VRL); F-ATP synthase epsilon chain (PDB ID: 5YIO) and RNA polymerase subunit C (PDB ID: 5ZX3)] as compared to respective classical drugs (Ethambutol, Levofloxacin, Pyrazinamide, Capreomycin, Isoniazid, Bedaquiline and Rifampicin). The optimized protein-ligand complexes used as input files for parameretization and simulation has been provided as “MDS_input_files” (https://data.mendeley.com/datasets/94rh86jfpk/3). The molecular dynamics parameter files along with the set of commands to run MDS are available as “MDS_parameter_files” (https://data.mendeley.com/datasets/94rh86jfpk/3). Fig. 1-3 represented the quality-check parameters after equilibrating certain protein-ligand complexes comprising classical and natural compounds prior to MD run depicting the electron Density, Pressure and Temperature levels [1]. The differences in molecular weight and number of atoms were reflected upon the electron density function of the individual protein-ligand complexes. The datasets for generating the figures has been provided explicitly in the Supplementary Files-8–14 (Figure_datasets) (https://data.mendeley.com/datasets/94rh86jfpk/3). The entire simulation dataset has been segmented appropriately based on the PDB IDs of the studied protein-targets. The different input and output files generated are made available under ``MD_simulation_files'' (https://data.mendeley.com/datasets/94rh86jfpk/3).
Fig. 1

Quality check parameters after equilibrating the respective protein-ligand complexes prior to MD run depicting the Density gradients, Pressure and Temperature levels. (A) 3PTY with Ethambutol and Glycyrrhizin, (B) 5KYG with Capreomycin and Glycyrrhizin, (C) 5VRL with Isoniazid and Glycyrrhizin.

Fig. 3

Quality check parameters after equilibrating the respective protein-ligand complexes prior to MD run depicting the Density gradients, Pressure and Temperature levels. (A) 4NNI with Pyrazinamide and Swertiamarin, (B) 5ZX3 with Rifampicin and Swertiamarin.

Quality check parameters after equilibrating the respective protein-ligand complexes prior to MD run depicting the Density gradients, Pressure and Temperature levels. (A) 3PTY with Ethambutol and Glycyrrhizin, (B) 5KYG with Capreomycin and Glycyrrhizin, (C) 5VRL with Isoniazid and Glycyrrhizin. Quality check parameters after equilibrating the respective protein-ligand complexes prior to MD run depicting the Density gradients, Pressure and Temperature levels. (A) 4G3N with Levofloxacin and Laccaic Acid, (B) 5YIO with Bedaquiline and Laccaic Acid.

Experimental Design, Materials and Methods

Seven Mtb proteins were selected, which are already targets of conventional anti-TB drugs [2]. Their 3D structures were obtained from RCSB-PDB (https://www.rcsb.org/), while the functional domains/motifs were obtained from InterPro (https://www.ebi.ac.uk/interpro/), Pfam (http://pfam.xfam.org/), and UniProt (https://www.uniprot.org/) databases. The classical drugs and the natural compounds were retrieved from the DrugBank (https://www.drugbank.com/) and PubChem Compound (https://pubchem.ncbi.nlm.nih.gov/) databases. ChemSketch tool [3] was employed in the absence of ligand structures for 2D structure construction followed by generation of 3D coordinates using the OpenBabel Chemical File Format Converter (http://www.cheminfo.org/Chemistry/Cheminformatics/FormatConverter/index.html). Further, the ligands were optimised with the Avogadro tool [4]. Molecular docking between the conventional anti-TB drugs and natural compounds with their respective targets was performed usingthe SYBYL-Surflex-docking tool kit (Tripos International, USA). The protein structures were refined to remove bound ligands and water molecules, fixing side chains, adding hydrogen atoms, followed by atomic-level charge designation using AMBER7 F99 force field. Thereafter, the proteins were energy minimised by Powell's method with Tripos force field followed by Protomol generation. Hammerhead functional scorings determined the polar, crash, entropic, hydrophobic and repulsive properties to yield the docked score datasets [5,6]. The MDS analyses for 75 nanoseconds (ns) was performed for each of the best-docked complexes with GROMACS 2018.1 suite [7]. Protein topologies were generated using CHARMM36-Mar2019 force-field mechanics and TIP3P model (for water cluster), while ligand topologies were built using CGenFF (https://cgenff.umaryland.edu/) online server with default parameters. The protein structures were placed within the center of the dodecahedron box of uniform edge distance of 1.0 nm, followed by solvation and addition of requisite counter ions (Na+ or Cl−) to the system. Steepest descent algorithm for 50,000 steps and convergence-tolerance of 1000 kJ/mol nm−1 were utilised for energy minimisation following system equilibration under standard NVT (constant Number of particles, Volume and Temperature) and NPT (constant Number of particles, Pressure and Temperature) ensembles for 100 ps [7], [8], [9], [10], [11], [12], [13], [14]. The trajectories of simulation parameters were visualised using Grace software (https://plasma-gate.weizmann.ac.il/Grace/). Quality check parameters after equilibrating the respective protein-ligand complexes prior to MD run depicting the Density gradients, Pressure and Temperature levels. (A) 4NNI with Pyrazinamide and Swertiamarin, (B) 5ZX3 with Rifampicin and Swertiamarin.

Ethics Statements

The work did not involve any human subjects, animal experiments and data from social media platforms.

CRediT authorship contribution statement

Sravan Kumar Miryala: Data curation, Formal analysis, Visualization, Writing – original draft. Soumya Basu: Formal analysis, Visualization, Writing – original draft. Aniket Naha: Formal analysis, Visualization, Writing – original draft. Reetika Debroy: Formal analysis, Visualization, Writing – original draft. Sudha Ramaiah: Conceptualization, Methodology, Validation, Writing – review & editing. Anand Anbarasu: Funding acquisition, Conceptualization, Project administration, Supervision. Saravanan Natarajan: Funding acquisition, Conceptualization, Project administration, Supervision.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
SubjectSubject area: Biological SciencesSub-section: Structural biology
Specific subject areaIn silico structural analyses of protein-ligand complexes with molecular dynamics based on chemical interactions
Type of dataTables and Figures
How the data were acquiredWe selected seven conventional drug targets in Mycobacterium tuberculosis whose 3D structures were downloaded from the Protein Data Bank (PDB) database (https://www.rcsb.org/). The structural and functional domains of the proteins were screened from UniProt (https://www.uniprot.org/), InterPro (https://www.ebi.ac.uk/interpro/) and Pfam (http://pfam.xfam.org/) databases. The ligand structures were acquired from the National centre for Biotechnology Information (NCBI) PubChem compound database (https://pubchem.ncbi.nlm.nih.gov/) and Drug bank database (https://www.drugbank.com/). The absence of a ligand structure in drug repositories was compensated by drawing the same with the ChemSketch tool followed by 3D structures generation using OpenBabel online server (http://www.cheminfo.org/Chemistry/Cheminformatics/FormatConverter/index.html). The bond integrities were validated using the Avogadro tool. The datasets comprising molecular docking scores of natural compounds (ligands) and the classical anti-Tuberculosis drugs with their respective targets were generated using the SYBYL-Surflex-docking tool kit. The best-docked complexes were subjected to topology adjustments for individual proteins and ligands using CHARMM36-Mar2019 force-field-TIP3P water-model and CGenFF (https://cgenff.umaryland.edu/) online server with default parameters respectively. The integrated simulation suite GROMACS 2018.1 was utilized. The optimized macromolecular complexes were solvated by centering in an aqueous dodecahedron box of uniform edge distance of 1.0 nm. Subsequently, requisite counter ions (Na+ or Cl) were added to balance the charges of the solvated system. Energy was minimized using integrated steepest descent algorithm for 50,000 steps and convergence-tolerance of 1000 kJ/mol nm−1. System equilibration with standard NVT (constant Number of particles, Volume and Temperature) and NPT (constant Number of particles, Pressure and Temperature) ensembles were performed for
100 ps. A constant pressure of 0 (zero) bar and temperature of 300 K with uniform density of ∼1040 kg/m3 was set for parameterization. Final molecular dynamics simulation (MDS) was carried out for 75 ns. Grace software was employed to visualize the trajectories of simulation parameters. A chronological list of commands and other associated parameter files to run simulation along with the entire MD-simulation files have been provided in the associated Mendeley dataset folder as mentioned in subsequent sections.
Data formatData is in raw and analysed form.
Description of data collectionThe structural chemistry data was acquired from authorised databases and repositories, followed by necessary optimisations using licensed (academic and professional) software. The reported docking scores and simulation parameters are based on universally accepted terms/standards.
Data source locationInstitution: Vellore Institute of Technology, VelloreCity/Town/Region: Vellore, Tamil NaduCountry: India
Data accessibilityData is available within this article and the raw data files in excel format and other standard formats for simulation has been uploaded on public repository and datasets with active link below is provided as the supplementary data.Link: (https://data.mendeley.com/datasets/94rh86jfpk/3),DOI: 10.17632/94rh86jfpk.3
Related research articleThe presented dataset is associated with our recent publication mentioned below[1]:S. K. Miryala, S. Basu, A. Naha, R. Debroy, S. Ramaiah, A. Anbarasu & S. Natarajan (2021). Identification of bioactive natural compounds as efficient inhibitors against Mycobacterium tuberculosis protein-targets: A molecular docking and molecular dynamics simulation study. Journal of Molecular Liquids341, 117,340. https://doi.org/10.1016/j.molliq.2021.117340
  11 in total

1.  Molecular dynamics simulations of wild-type and mutant forms of the Mycobacterium tuberculosis MscL channel.

Authors:  D E Elmore; D A Dougherty
Journal:  Biophys J       Date:  2001-09       Impact factor: 4.033

2.  Personal experience with four kinds of chemical structure drawing software: review on ChemDraw, ChemWindow, ISIS/Draw, and ChemSketch.

Authors:  Zhenjiang Li; Honggui Wan; Yuhu Shi; Pingkai Ouyang
Journal:  J Chem Inf Comput Sci       Date:  2004 Sep-Oct

3.  Structural insight into conformational dynamics of non-active site mutations in KasA: A Mycobacterium tuberculosis target protein.

Authors:  Manikandan Jayaraman; Savita Kumari Rajendra; Krishna Ramadas
Journal:  Gene       Date:  2019-08-30       Impact factor: 3.688

4.  Molecular Docking and Molecular Dynamics Studies to Identify Potential OXA-10 Extended Spectrum β-Lactamase Non-hydrolysing Inhibitors for Pseudomonas aeruginosa.

Authors:  Kullappan Malathi; Sudha Ramaiah
Journal:  Cell Biochem Biophys       Date:  2016-05-27       Impact factor: 2.194

5.  Genome sequencing and molecular characterisation of XDR Acinetobacter baumannii reveal complexities in resistance: Novel combination of sulbactam-durlobactam holds promise for therapeutic intervention.

Authors:  Aniket Naha; Saranya Vijayakumar; Binesh Lal; Baby A Shankar; Suriya Chandran; Sudha Ramaiah; Balaji Veeraraghavan; Anand Anbarasu
Journal:  J Cell Biochem       Date:  2021-10-01       Impact factor: 4.429

6.  Molecular docking and dynamics studies on novel benzene sulfonamide substituted pyrazole-pyrazoline analogues as potent inhibitors of Plasmodium falciparum Histo aspartic protease.

Authors:  Mahalakshmi Thillainayagam; Sudha Ramaiah; Anand Anbarasu
Journal:  J Biomol Struct Dyn       Date:  2019-08-24

7.  In silico structure evaluation of BAG3 and elucidating its association with bacterial infections through protein-protein and host-pathogen interaction analysis.

Authors:  Soumya Basu; Aniket Naha; Balaji Veeraraghavan; Sudha Ramaiah; Anand Anbarasu
Journal:  J Cell Biochem       Date:  2021-05-17       Impact factor: 4.429

8.  Avogadro: an advanced semantic chemical editor, visualization, and analysis platform.

Authors:  Marcus D Hanwell; Donald E Curtis; David C Lonie; Tim Vandermeersch; Eva Zurek; Geoffrey R Hutchison
Journal:  J Cheminform       Date:  2012-08-13       Impact factor: 5.514

9.  Demystifying the catalytic pathway of Mycobacterium tuberculosis isocitrate lyase.

Authors:  Collins U Ibeji; Nor Amirah Mohd Salleh; Jia Siang Sum; Angela Chiew Wen Ch'ng; Theam Soon Lim; Yee Siew Choong
Journal:  Sci Rep       Date:  2020-11-03       Impact factor: 4.379

10.  Novel cyclohexanone compound as a potential ligand against SARS-CoV-2 main-protease.

Authors:  Soumya Basu; Balaji Veeraraghavan; Sudha Ramaiah; Anand Anbarasu
Journal:  Microb Pathog       Date:  2020-10-01       Impact factor: 3.738

View more
  1 in total

1.  A New Perspective on the Antimicrobial Mechanism of Berberine Hydrochloride Against Staphylococcus aureus Revealed by Untargeted Metabolomic Studies.

Authors:  Shu Wu; Kun Yang; Yuhang Hong; Yanju Gong; Jiajia Ni; Ni Yang; Weijun Ding
Journal:  Front Microbiol       Date:  2022-07-13       Impact factor: 6.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.